A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Puig, Teresa ^a,b   Aguilar, Helena ^c   Cufí, Sílvia ^a   Oliveras, Glòria ^a   Turrado, Carlos ^d   Ortega Gutiérrez, Sílvia ^d   Benhamú, Bellinda ^d   López Rodríguez, María L ^d   Urruticoechea, Ander ^c   Colomer, Ramon ^e  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e MD ANDERSON CANCER CENTER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS [(3,4,5 THIHYDROXYBENZOIL)OXY]NAPHTHALENE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; G 28 UCM; GEFITINIB; HEMOGLOBIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; 1,3 BIS((3,4,5 TRIHYDROXYBENZOYL)OXY)NAPHTHALENE; 1,3-BIS((3,4,5-TRIHYDROXYBENZOYL)OXY)NAPHTHALENE; ENZYME INHIBITOR; GALLIC ACID; NAPHTHALENE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEMATOCRIT; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; SIGNAL TRANSDUCTION; THROMBOCYTE; TREATMENT RESPONSE; TUMOR VOLUME; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GALLIC ACID; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NAPHTHALENES; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83455237864     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3077     Document Type: Article

References (50)

1. Menendez JA, Lupu R, Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in HER-2/neu overexpressing breast cancer. Drug News Perspect 2005, 18:375-385. 10.1358/dnp.2005.18.6.927929, 16247515.
2. Vergote D, Cren-Olivé C, Chopin V, Toillon RA, Rolando C, Hondermarck, Le Bourhis X. (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human. breast cancer cells but not of their normal counterparts. Breast Cancer Treat 2002, 76:195-201.
3. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004, 101:10715-10720. 10.1073/pnas.0403390101, 490000, 15235125.
4. Puig T, Vazquez-Martin A, Relat J, Pétriz J, Menéndez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J, Colomer R. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 2008, 109:471-479. 10.1007/s10549-007-9678-5, 17902053.
5. Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun 2009, 385:454-459. 10.1016/j.bbrc.2009.05.085, 19467222.
6. Puig T, Relat J, Marrero PF, Haro D, Brunet J, Colomer R. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Res 2008, 28:3671-3676.
7. Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res 2001, 7:153-157.
8. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005, 65:6719-6725. 10.1158/0008-5472.CAN-05-0571, 16061653.
9. Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, Weinstein IB. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005, 11:2735-2746. 10.1158/1078-0432.CCR-04-2014, 15814656.
10. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, Dou QP. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007, 67:4303-4310. 10.1158/0008-5472.CAN-06-4699, 17483343.
11. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2005, 24:39-46. 10.1038/sj.onc.1208174, 15489885.
12. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005, 24:3574-3582. 10.1038/sj.onc.1208463, 15806173.
13. Puig T, Turrado C, Benhamú B, Aguilar H, Relat J, Ortega-Gutiérrez S, Casals G, Marrero PF, Urruticoechea A, Haro D, López-Rodríguez ML, Colomer R. Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. Clin Cancer Res 2009, 15:7608-7615. 10.1158/1078-0432.CCR-09-0856, 20008854.
14. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 2002, 62:642-646.
15. Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R. Novel signaling molecules implicated in tumour-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53- p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 2004, 24:591-608.
16. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, Park BW, Kim KS. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 2007, 282:26122-26131. 10.1074/jbc.M702854200, 17631500.
17. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 2008, 41:59-85. 10.1111/j.1365-2184.2007.00498.x, 18211286.
18. Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun 2009, 385:454-459. 10.1016/j.bbrc.2009.05.085, 19467222.
19. Shaw RJ, Cantley LC. Ras, PI (3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430. 10.1038/nature04869, 16724053.
20. Kim KJ, Kim HY, Cho HK, Kim KH, Cheong J. The SDF-1alpha/CXCR4 axis induces the expression of fatty acid synthase via sterol regulatory element binding protein-1 activation in cancer cells. Carcinogenesis 2010, 31:679-686. 10.1093/carcin/bgp329, 20067991.
21. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009, 101:519-532. 10.1093/jnci/djp030, 2664091, 19318631.
22. Sabbisetti V, Di Napoli A, Seeley A, Amato AM, O'Regan E, Ghebremichael M, Loda M, Signoretti S. p63 promotes cell survival through fatty acid synthase. PLoS One 2009, 4:e5877. 10.1371/journal.pone.0005877, 2691576, 19517019.
23. Siddiqui RA, Harvey KA, Zaloga GP, Stillwell W. Modulation of lipid rafts by omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support. Nutr Clin Pract 2007, 22:74-88. 10.1177/011542650702200174, 17242459.
24. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000, 288:2379-2381. 10.1126/science.288.5475.2379, 10875926.
25. Hu Z, Cha SH, Chohnan S, Lane MD. Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci USA 2003, 100:12624-12629. 10.1073/pnas.1834402100, 240668, 14532332.
26. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci USA 2002, 99:9498-9502. 123169, 12060712.
27. Nicot C, Napal L, Relat J, González S, Llebaria A, Woldegiorgis G, Marrero PF, Haro D. C75 activates malonyl-CoA sensitive and insensitive components of the CPT system. Biochem Biophys Res Commun 2004, 325:660-664. 10.1016/j.bbrc.2004.10.085, 15541339.
28. Aja S, Landree LE, Kleman AM, Medghalchi SM, Vadlamudi A, McFadde JM, Aplasca A, Hyun J, Plummer E, Daniels K, Kemm M, Townsend CA, Thupari JN, Kuhajda FP, Moran TH, Ronnett GV. Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight. Am J Physiol Regul Integr Comp Physiol 2008, 294:352-361.
29. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97:1442-1446. 10.1002/cncr.11200, 12627508.
30. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005, 81:230S-242S.
31. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 2009, 15:7479-7491. 10.1158/1078-0432.CCR-09-0636, 20008848.
32. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010, 7:98-107. 10.1038/nrclinonc.2009.216, 20027191.
33. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumour inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127. 10.1016/j.ccr.2004.06.022, 15324695.
34. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99:628-638. 10.1093/jnci/djk134, 17440164.
35. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3 kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230. 10.1158/0008-5472.CAN-08-1740, 2587064, 19010894.
36. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin like growth factor I receptor signaling and resistance to trastuzumab (herceptin). J. Natl Cancer Inst 2001, 93:1852-1857. 10.1093/jnci/93.24.1852, 11752009.
37. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009, 15:7381-7388. 10.1158/1078-0432.CCR-09-1735, 2788123, 19920100.
38. Vazquez-Martin A, Colomer R, Brunet J, Menendez JA. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol 2007, 31:769-776.
39. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) downregulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004, 64:3981-3986. 10.1158/0008-5472.CAN-03-3900, 15173011.
40. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007, 6:667-674. 10.1158/1535-7163.MCT-06-0423, 17308062.
41. Ropero S, Menéndez JA, Vázquez-Martín A, Montero S, Cortés-Funes H, Colomer R. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 2004, 86:125-137. 10.1023/B:BREA.0000032981.20384.c6, 15319565.
42. Menendez JA, Lupu R, Colomer R. Inhibition of tumour-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/neu - overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treat 2004, 84:183-195. 10.1023/B:BREA.0000018409.59448.60, 14999148.
43. Orita H, Coulter J, Tully E, Kuhajda FP, Gabrielson E. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumours. Clin Cancer Res 2008, 15:2458-2464.
44. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Badve S, Nakshatri H. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8:R59. 10.1186/bcr1610, 1779499, 17062128.
45. Sen T, Dutta A, Chatterjee A. Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs 2010, 21:632-644. 10.1097/CAD.0b013e32833a4385, 20527725.
46. Punathil T, Tollefsbol TO, Katiyar SK. EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase. Biochem Biophys Res Comun 2008, 10:162-167.
47. Satoh K, Sakamoto Y, Ogata A, Nagai F, Mikuriya H, Numazawa M, Yamada K, Aoki N. Inhibition of aromatase activity by green tea extracts catechins and their endocrinological effects of oral administration in rats. Food Chem Toxicol 2002, 40:925-933. 10.1016/S0278-6915(02)00066-2, 12065214.
48. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336. 10.1038/nbt1068, 15711537.
49. Schaefer G, Shao L, Totpal K, Akita RW. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 2007, 67:1228-1238. 10.1158/0008-5472.CAN-06-3493, 17283159.
50. Eddy SF, Kane SE, Sonenshein GE. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. Cancer Res 2007, 67:9018-9023. 10.1158/0008-5472.CAN-07-1691, 17909003.